Abstract
Objective: We aim to delineate the progression of cerebellar atrophy (the primary neuroimaging finding) in children with phosphomannomutase-deficiency (PMM2-CDG) by analyzing longitudinal MRI studies and performing cerebellar volumetric analysis and a 2D cerebellar measurement. Methods: Statistical analysis was used to compare MRI measurements [midsagittal vermis relative diameter (MVRD) and volume] of children with PMM2-CDG and sex- and age-matched controls, and to determine the rate of progression of cerebellar atrophy at different ages. Ethical permission was obtained from our Research & Ethics Committee. Statistical analysis was performed using SPSS V.22.0. Results: Fifty MRI studies of 33 PMM2-CDG patients were used for 2D evaluation, and 19 MRI studies were available for volumetric analysis. Results from linear regression model showed that patients have significantly lower MVRD and cerebellar volume compared to controls (p<0.001 and p<0.001 respectively). There was a significant negative correlation between age and MVRD for patients (p=0.014). The rate of cerebellar atrophy measured by the loss of MVRD and cerebellar volume per year was higher at early ages (r=−0.578, p=0.012 and r=−0.323, p=0.48 respectively), particularly in patients under 11 years (p=0.004). There was a significant positive correlation between MVRD and cerebellar volume in PMM2-CDG patients (r=0.669, p=0.001). Conclusion: To our knowledge, this is the first study in PMM2-CDG patients in which a volumetric method is applied to evaluate the cerebellar atrophy. Our study quantifies a progression of cerebellar atrophy, particularly during the first decade of life, and suggests a simple and reliable measure, the MVRD, to monitor cerebellar atrophy. Quantitative measurement of MVRD and cerebellar volume are essential for correlation with phenotype and outcome, as well as natural follow-up. The description of the natural radiological evolution of the cerebellum in PMM2-CDG and the use of radiologic quantitative methods are essential to quantify cerebellum changes in case of potential therapies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.